Fosun Pharma stock has October 27 results on its calendar

Published on 10/15/2026 at 21:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fosun Pharma's market value was CNY 61.2 billion on October 15, 2026. Fosun Pharma stock costs EUR 1.96 on October 15, 2026 at 9:09 p.m. CEST.

Dates and valuation guide Fosun Pharma

Fosun Pharma will consider its nine-month results on October 27, 2026, according to a dated board notice.
Fosun Pharma's market capitalization stood at CNY 61.2 billion on October 15, 2026.
Fosun Pharma stock costs EUR 1.96 at Lang & Schwarz on October 15, 2026 at 9:09 p.m. CEST.
Fosun Pharma's price-to-earnings ratio was 18.12 on October 15, 2026.

Fosun Pharma, CNE100001M79, Illustration mit AI erstellt.

Fosun Pharma will consider and release its results for the nine months ending September 30, 2026, at a board meeting on October 27, 2026, according to Futubull. The date gives investors the next fixed point for assessing revenue, earnings and cash generation. Fosun Pharma stock was trading at EUR 1.96 at Lang & Schwarz on October 15, 2026 at 9:09 p.m. CEST.

Business base and coming results

Fosun Pharma describes itself as a pharmaceutical and healthcare group active in drug manufacturing, medical devices, diagnostics and healthcare services. The company also holds a stake in Sinopharm Group and says its research pipeline covers small-molecule drugs, antibodies and cell therapies, according to its Fosun Pharma investor relations page.

The October 27 meeting concerns the third-quarter results for the nine months ended September 30, 2026. The board notice was dated October 12, 2026, and identifies the reporting period rather than providing the figures themselves.

Stock position in Shanghai

The Shanghai-listed shares last traded at CNY 23.19 on October 15, 2026 at 3:00 p.m. CST. The session change was minus 0.34 percent from CNY 23.27, while volume reached 16,965,789 shares against an average of 25,788,395. The 52-week range was CNY 20.85 to CNY 29.68, placing the latest Shanghai price 21.86 percent above the low and 21.88 percent below the high.

Valuation and market size

Fosun Pharma had a market capitalization of CNY 61.2 billion on October 15, 2026, with a price-to-earnings ratio of 18.12. That multiple sits below Jiangsu Hengrui Medicine's 39.83 and Beijing Tongrentang's 34.94 on the same date, while Fosun Pharma's market value was smaller than Jiangsu Hengrui Medicine's CNY 297.3 billion and larger than Beijing Tongrentang's CNY 34.0 billion.

Comparison with peers

Fosun Pharma: minus 0.34 percent, P/E 18.12, market capitalization CNY 61.2 billion

Jiangsu Hengrui Medicine (Shanghai Stock Exchange, CNY): plus 2.44 percent, P/E 39.83, market capitalization CNY 297.3 billion

Beijing Tongrentang (Shanghai Stock Exchange, CNY): plus 0.41 percent, P/E 34.94, market capitalization CNY 34.0 billion

Next date for investors

The October 27 board meeting is the next scheduled corporate date cited for Fosun Pharma. Its results will provide the next quantified comparison with the nine-month reporting period and clarify whether the company is maintaining the growth path described in its investor materials.

Price and investor view

The key contrast is between Fosun Pharma's CNY 61.2 billion Shanghai valuation and its EUR 1.96 German-market indication after hours. The scheduled results date gives the stock a concrete near-term calendar point, while the 52-week range shows that the Shanghai price remains below its yearly high.

Fosun Pharma was trading at EUR 1.96 at Lang & Schwarz on October 15, 2026 at 9:09 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Fosun Pharma stock.